Medexus Pharmaceuticals Valuation
| MEDXF Stock | USD 1.96 0.05 2.49% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Medexus Pharmaceuticals secures a last-minute Real Value of $1.73 per share. The latest price of the firm is $1.96. Our model forecasts the value of Medexus Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of 80.42 M, profit margin of (0.11) %, and Return On Equity of -0.57 as well as examining its technical indicators and probability of bankruptcy. . In general, most investors recommend locking in undervalued stocks and disposing overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Overvalued
Today
Please note that Medexus Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of Medexus Pharmaceuticals is based on 3 months time horizon. Increasing Medexus Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Medexus otc stock is determined by what a typical buyer is willing to pay for full or partial control of Medexus Pharmaceuticals. Since Medexus Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Medexus OTC Stock. However, Medexus Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.96 | Real 1.73 | Hype 1.96 | Naive 1.94 |
The real value of Medexus OTC Stock, also known as its intrinsic value, is the underlying worth of Medexus Pharmaceuticals OTC Stock, which is reflected in its stock price. It is based on Medexus Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Medexus Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Medexus Pharmaceuticals helps investors to forecast how Medexus otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Medexus Pharmaceuticals more accurately as focusing exclusively on Medexus Pharmaceuticals' fundamentals will not take into account other important factors: Medexus Pharmaceuticals Total Value Analysis
Medexus Pharmaceuticals is now anticipated to have takeover price of 80.42 M with market capitalization of 23.56 M, debt of 39.82 M, and cash on hands of 7.29 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Medexus Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
80.42 M | 23.56 M | 39.82 M | 7.29 M |
Medexus Pharmaceuticals Investor Information
The company has price-to-book ratio of 1.75. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Medexus Pharmaceuticals last dividend was issued on the 19th of December 2018. The entity had 1:15 split on the 19th of December 2018. Based on the key indicators related to Medexus Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Medexus Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in August.Medexus Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Medexus Pharmaceuticals has an asset utilization ratio of 55.09 percent. This implies that the OTC Stock is making $0.55 for each dollar of assets. An increasing asset utilization means that Medexus Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Medexus Pharmaceuticals Ownership Allocation
Medexus Pharmaceuticals maintains a total of 20.14 Million outstanding shares. Medexus Pharmaceuticals secures 11.0 % of its outstanding shares held by insiders and 0.38 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Medexus Pharmaceuticals Profitability Analysis
The company reported the revenue of 76.7 M. Net Loss for the year was (2.88 M) with profit before overhead, payroll, taxes, and interest of 43.67 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Medexus Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Medexus Pharmaceuticals and how it compares across the competition.
About Medexus Pharmaceuticals Valuation
The otc valuation mechanism determines Medexus Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Medexus Pharmaceuticals. We calculate exposure to Medexus Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Medexus Pharmaceuticals's related companies.Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 100 people.
8 Steps to conduct Medexus Pharmaceuticals' Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Medexus Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Medexus Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Medexus Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Medexus Pharmaceuticals' revenue streams: Identify Medexus Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Medexus Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Medexus Pharmaceuticals' growth potential: Evaluate Medexus Pharmaceuticals' management, business model, and growth potential.
- Determine Medexus Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Medexus Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Medexus Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Medexus Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 20 M | |
| Forward Price Earnings | 133.3333 | |
| Retained Earnings | -65.2 M |
Complementary Tools for Medexus OTC Stock analysis
When running Medexus Pharmaceuticals' price analysis, check to measure Medexus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medexus Pharmaceuticals is operating at the current time. Most of Medexus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Medexus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medexus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Medexus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |